Study Could Resolve Abiraterone/Docetaxel Debate in Hormone-Sensitive Prostate Cancer

Andy Hahn, MD, discusses the ongoing debate between abiraterone and docetaxel and the optimal patient selection for each agent in patients with metastatic hormone-sensitive prostate cancer.

More From BioPortfolio on "Study Could Resolve Abiraterone/Docetaxel Debate in Hormone-Sensitive Prostate Cancer"